REFERENCES
1.
Carabelli
A M, Peacock T P, Thorne L G, et al. SARS-CoV-2 variant biology: immune
escape, transmission and fitness. Nat Rev Microbiol .
2023;21(3):162-177.
2.
Shrestha
L B, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron
variants BA.1 to BA.5: Implications for immune escape and
transmission. Rev Med Virol . 2022;32(5):e2381.
3.
World
Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023;
Available online: https://covid19.who.int/ (accessed on 2 November
2023).
4.
Wang W
C, Sayedahmed E E, Sambhara S, et al. Progress towards the Development
of a Universal Influenza Vaccine. Viruses . 2022;14(8).
5.
Swets
M C, Russell C D, Harrison E M, et al. SARS-CoV-2 co-infection with
influenza viruses, respiratory syncytial virus, o adenoviruses.
Lancet . 2022;399(10334):1463-1464.
6.
Bowe
B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with
SARS-CoV-2 reinfection. Nat Med . 2022;28(11):2398-2405.
7. Su
S, Liu Z, Jiang S. Double insult: flu bug enhances SARS-CoV-2
infectivity. Cell Res . 2021;31(5):491-492.
8. Ye
Q, Wu M, Zhou C, et al. Rational development of a combined mRNA vaccine
against COVID-19 and influenza. NPJ Vaccines . 2022;7(1):84.
9.
Tripp
R A. Understanding immunity to influenza: implications for future
vaccine development. Expert Rev Vaccines . 2023;22(1):871-875.
10.
Liu Q,
Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in
real-world studies: a systematic review and meta-analysis. Infect
Dis Poverty . 2021;10(1):132.
11.
Mohamed
K, Rzymski P, Islam M S, et al. COVID-19 vaccinations: The unknowns,
challenges, and hopes. J Med Virol . 2022;94(4):1336-1349.
12.
Chaparian
R R, Harding A T, Hamele C E, et al. A Virion-Based Combination Vaccine
Protects against Influenza and SARS-CoV-2 Disease in Mice. J
Virol . 2022;96(15):e68922.
13.
Chen
J, Wang P, Yuan L, et al. A live attenuated virus-based intranasal
COVID-19 vaccine provides rapid, prolonged, and broad protection against
SARS-CoV-2. Sci Bull (Beijing) . 2022;67(13):1372-1387.
14.
Shi R,
Zeng J, Xu L, et al. A combination vaccine against SARS-CoV-2 and H1N1
influenza based on receptor binding domain trimerized by six-helix
bundle fusion core. EBioMedicine . 2022;85:104297.
15.
Wang
Z, Li Z, Shi W, et al. A SARS-CoV-2 and influenza double hit vaccine
based on RBD-conjugated inactivated influenza A virus. Sci Adv .
2023;9(25):o4100.
16.
Cao K,
Wang X, Peng H, et al. A Single Vaccine Protects against SARS-CoV-2 and
Influenza Virus in Mice. J Virol . 2022;96(4):e157821.
17. Ao
Z, Ouyang M J, Olukitibi T A, et al. A Recombinant VSV-Based Bivalent
Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A
Virus Infection. J Virol . 2022;96(18):e133722.
18.
Zhang
N, Ji Q, Liu Z, et al. Effect of Different Adjuvants on Immune Responses
Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its
Delta Variant. Viruses . 2022;14(3).
19.
Liu Z,
Xu W, Chen Z, et al. An ultrapotent pan-β-coronavirus lineage B
(β-CoV-B) neutralizing antibody locks the receptor-binding domain in
closed conformation by targeting its conserved epitope. Protein
Cell . 2022;13(9):655-675.
20.
Zhou
Y, Liu Z, Li S, et al. Enhancement versus neutralization by SARS-CoV-2
antibodies from a convalescent donor associates with distinct epitopes
on the RBD. Cell Rep . 2021;34(5):108699.
21.
Cheng
Y, Ma J, Wang H, et al. Co-infection of influenza A virus and
SARS-CoV-2: A retrospective cohort study. J Med Virol .
2021;93(5):2947-2954.